Abstract:The (R)-enantiomer of 2-hydroxyglutarate, which is produced when IDH is mutated in human tumours, is shown to stimulate the activity of the EGLN prolyl 4-hydroxylases, leading to diminished levels of HIF and enhanced human astrocyte proliferation. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 have been identified in gliomas, the most common form of brain tumour, and in other cancers including leukaemias. The mutated enzymes produce 2-hydroxyglutarate (2HG), which is a potential oncometabolite. Three papers in this issue of Nature examine the mechanisms through which IDH mutations promote cancers. Lu et al. show that 2HG-producing IDH mutants can prevent the histone demethylation that is required for progenitor cells to differentiate, potentially contributing to tumour-cell accumulation. Turcan et al. show that IDH1 mutation in primary human astrocytes induces DNA hypermethylation and reshapes the methylome to resemble that of the CIMP phenotype, a common feature of gliomas and other solid tumours. Koivunen et al. show that the (R)-enantiomer of 2HG (but not the (S)-enantiomer) can stimulate the activity of the EGLN prolyl 4-hydroxylases, leading to diminished levels of hypoxia-inducible factor (HIF), which in turn can enhance cell proliferation. These papers establish a framework for understanding gliomagenesis and highlight the interplay between genomic and epigenomic changes in human cancers. The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation1. Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG)2,3. Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.

P08.65 the Mechanisms of Oncometabolites in Epigenetic Control, DNA Repair, Neural Development and Gliomagenesis

Oncometabolite 2-Hydroxyglutarate is a Competitive Inhibitor of Α-Ketoglutarate-dependent Dioxygenases

Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation

Metabolism, Activity, and Targeting of D-and L-2-Hydroxyglutarates

Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.

The oncometabolite D-2-hydroxyglutarate promotes DNA hypermethylation at lineage-specific enhancers controlling microglial activation in IDHmut gliomas

The Mechanisms of IDH Mutations in Tumorigenesis

IDH1 Mutation Inhibits Differentiation of Astrocytes and Glioma Cells with Low Oxoglutarate Dehydrogenase Expression by Disturbing Α-Ketoglutarate-related Metabolism and Epigenetic Modification

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

Deciphering the Multifaceted Roles and Clinical Implications of 2-Hydroxy-glutarate in Cancer

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma

D-2-hydroxyglutarate is Essential for Maintaining Oncogenic Property of Mutant IDH-containing Cancer Cells but Dispensable for Cell Growth

P89.07 A Large-Scale Survey of IDH1/2 Mutation in Chinese Patients with NSCLC

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

IDH1/2 Mutations Target a Key Hallmark of Cancer by Deregulating Cellular Metabolism in Glioma

Lactate dehydrogenase A silencing in IDH mutant gliomas

Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma

Profiling The Effects Of Isocitrate Dehydrogenase 1 And 2 Mutations On The Cellular Metabolome

Deciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer

TAMI-14. REDUCTION IN S. CEREVISIAE GROWTH AND CELL VIABILITY IN RESPONSE TO D-2-HYDROXYGLUTARATE ACCUMULATION IS DAMPENED BY GROWTH CONDITIONS PERMISSIVE OF OXIDATIVE PHOSPHORYLATION